↓ Skip to main content

Dove Medical Press

Article Metrics

Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis

Overview of attention for article published in Therapeutics and Clinical Risk Management, July 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#48 of 954)
  • High Attention Score compared to outputs of the same age (85th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

blogs
1 blog
twitter
4 tweeters
facebook
1 Facebook page
wikipedia
1 Wikipedia page

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
40 Mendeley
Title
Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
Published in
Therapeutics and Clinical Risk Management, July 2017
DOI 10.2147/tcrm.s134398
Pubmed ID
Authors

Cristina Guarnera, Placido Bramanti, Emanuela Mazzon

Abstract

Alemtuzumab is a selective humanized monoclonal antibody directed against the CD52 antigen, and has been found to be a powerful treatment for relapsing remitting multiple sclerosis. Alemtuzumab demonstrated high efficacy in several clinical studies. The risk of relapse and sustained accumulation of disability showed significant reduction in the Phase II CAMMS223 and the Phase III clinical trials CARE MS I and CARE MS II. The data presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis confirmed these results. After completion of a 1-year treatment cycle, alemtuzumab showed a sustained effect. Although the efficacy of alemtuzumab has been widely proven, several severe adverse effects have been reported with its use. Infusion-associated reactions, increased risk of infections, and secondary autoimmunity have been associated with alemtuzumab. Autoimmune disease - mainly of the thyroid - has been reported. Immune thrombocytopenic purpura and autoimmune nephropathies have been observed less frequently. These adverse effects, given the short period of alemtuzumab marketing for relapsing remitting multiple sclerosis, require strict monitoring.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 40 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 12 30%
Unspecified 7 18%
Researcher 6 15%
Student > Ph. D. Student 4 10%
Student > Doctoral Student 4 10%
Other 7 18%
Readers by discipline Count As %
Medicine and Dentistry 13 33%
Unspecified 11 28%
Agricultural and Biological Sciences 4 10%
Biochemistry, Genetics and Molecular Biology 3 8%
Nursing and Health Professions 2 5%
Other 7 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 April 2019.
All research outputs
#1,169,519
of 13,160,482 outputs
Outputs from Therapeutics and Clinical Risk Management
#48
of 954 outputs
Outputs of similar age
#39,075
of 265,850 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#3
of 21 outputs
Altmetric has tracked 13,160,482 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 954 research outputs from this source. They receive a mean Attention Score of 4.4. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,850 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.